Final guidance from FDA regarding adverse event report (AER) labeling for dietary supplements requires either a domestic phone number or a three-line address by September 30, 2010, according to a recently published notice. Under the Dietary Supplement and Nonprescription Drug Consumer Protection Act, a “responsible person” is required to submit to FDA within 15 days any serious adverse event it receives in association with its products. FDA’s final guidance states that a conforming phone number must include the area code (and clarifies with an example that a toll-free number is acceptable), and that a conforming domestic address must include a street address or P.O. box, along with the city, state and zip code. Current labeling rules require identification of only the city, state and zip code, as long as the firm’s street address is listed in a current telephone directory or other city directory. FDA’s final guidance also states that a label may include an e-mail address or website to which reports may be made, so long as the domestic phone number or domestic address is also present on the label. FDA maintains in the final draft document a recommendation that “the label also bear a clear, prominent statement informing consumers that they may report serious adverse events to the domestic address or domestic phone number on the label.”

In language new to the guidance, FDA also indicated that this recommended signal statement may contain additional information, noting “the responsible person can also clarify that a doctor should be called for medical advice.” The American Herbal Products Association (AHPA), Silver Spring, MD, noted the agency also states in the guidance that the law “does not require a label to include anything other than a domestic address or domestic phone number for the responsible person.” Further, as FDA establishes at the beginning of the document: “FDA’s guidance documents, including this document, do not establish legally enforceable responsibilities.”

“AHPA is appreciative of FDA’s decision to provide an extended period of enforcement discretion, and encourages member companies to promptly review labels for inclusion of a domestic phone number or address,” said AHPA president Michael McGuffin. “At the same time, AHPA continues to have concerns about the shortcut to rulemaking expressed by FDA’s signal language recommendation, and the agency’s unwillingness to accept the clearly stated intent of Congress. Companies may want to consider the limits of their actual legal responsibility when determining whether to adopt FDA’s recommendation for use of this signal language.”